Catalent Partners with Galapagos to Support Decentralized CAR-T Manufacturing for NHL Trials

  • Catalent, Inc. has entered into a strategic collaboration with Galapagos NV to support decentralized manufacturing for Galapagos’ investigational CAR-T therapy, GLPG5101, for non-Hodgkin lymphoma (NHL) trials.
  • Catalent’s commercial cell therapy facility in Princeton, New Jersey, will be responsible for supporting the manufacturing process for upcoming clinical studies in New Jersey, New York, and surrounding areas.

Catalent, Inc. has announced a new strategic collaboration with Galapagos NV, a biotechnology company, to support the decentralized manufacturing of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed or refractory non-Hodgkin lymphoma (NHL). This partnership aims to assist in the clinical trials of the therapy across New Jersey, New York, and surrounding regions.

The collaboration will leverage Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey. The facility will play a crucial role in supporting the innovative decentralized manufacturing platform developed by Galapagos. This model, which places manufacturing closer to cancer treatment centers, is designed to reduce logistical barriers and improve access to therapies for patients.

Galapagos’ approach has shown promise in treating patients with NHL, even those who have previously failed other therapies. By shortening the vein-to-vein time to a median of seven days, the platform helps avoid cryopreservation and eliminates the need for bridging therapy, ensuring that fresh, early memory cell therapies reach patients faster.

“We are delighted by this collaboration to support Galapagos’ decentralized cell therapy approach to bring these pioneering treatments to more patients with certain aggressive forms of NHL in a median vein-to-vein time of seven days,” said Delara Motlagh, Vice President, Global Cell Therapy and Plasmid DNA at Catalent. The collaboration underscores Catalent’s commitment to increasing patient access to life-changing therapies, particularly for patients with aggressive forms of cancer like NHL.

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.